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Abstract
Resolution of chronic hepatitis C is considered when serum HCV RNA becomes repeatedly undetectable and liver enzymes
normalize. However, long-term persistence of HCV following therapy with pegylated interferon-a/ribavirin (PegIFN/R) was
reported when more sensitive assays and testing of serial plasma, lymphoid cells (PBMC) and/or liver biopsies was applied.
Our aim was to reassess plasma and PBMCs collected during and after standard PegIFN/R therapy from individuals who
became HCV RNA nonreactive by clinical testing. Of particular interest was to determine if HCV genome and its replication
remain detectable during ongoing treatment with PegIFN/R when evaluated by more sensitive detection approaches.
Plasma acquired before (n = 11), during (n = 25) and up to 12–88 weeks post-treatment (n = 20) from 9 patients and PBMC
(n = 23) from 3 of them were reanalyzed for HCV RNA with sensitivity ,2 IU/mL. Clone sequencing of the HCV 59-
untranslated region from plasma and PBMCs was done in 2 patients. HCV RNA was detected in 17/25 (68%) plasma and 8/10
(80%) PBMC samples collected from 8 of 9 patients during therapy, although only 5.4% plasma samples were positive by
clinical assays. Among post-treatment HCV RNA-negative plasma samples, 9 of 20 (45.3%) were HCV reactive for up to 59
weeks post-treatment. Molecularly evident replication was found in 6/12 (50%) among PBMC reactive for virus RNA positive
strand collected during or after treatment. Pre-treatment point mutations persisted in plasma and/or PBMC throughout
therapy and follow-up. Therefore, HCV is not completely cleared during ongoing administration of PegIFN/R otherwise
capable of ceasing progression of CHC and virus commonly persists at levels not detectable by the current clinical testing.
The findings suggest the need for continued evaluation even after patients achieve undetectable HCV RNA post-treatment.
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Introduction
Hepatitis C virus (HCV) is a single-stranded RNA virus that is
the cause of clinically diagnosable chronic infection in approxi-
mately 170 million people worldwide. Of those acutely afflicted,
15% spontaneously resolve hepatitis, while the remaining develop
chronic hepatitis C (CHC) [1]. Up to15% of the patients with
CHC progress to fibrosis and cirrhosis, and they are at a greater
risk of developing hepatocellular carcinoma (HCC) [2]. HCV is
infectious even in trace amounts, with approximately 10 virions or
20 copies of viral RNA capable of transmitting infection in
chimpanzees [3,4] and with 20 to 50 virions able to establish
productive infection in human T cells in vitro [5]. The introduction
of nucleic acid amplification assays detecting HCV genomes with
high sensitivity, i.e.,,10 virus genome equivalents (vge) or copies/ml
or ,2.5 vge/mg RNA (,2 IU/ml), revealed that HCV persists at
low levels (usually below 100 vge/ml) for years after clinical
resolution of hepatitis either spontaneously or due to treatment with
interferon-a (IFN) alone or pegylated IFN/ribavirin (PegIFN/R)
[6,7]. The long-term consequences of this essentially asymptomatic
infection, termed as occult HCV infection (OCI), remains
uncertain; however, OCI coincides with histologically evident
protracted low grade liver inflammation and fibrosis in some
patients for at least 10 years after completion of antiviral treatment
[8–11]. Also, clinically diagnosed sustained virological response
(SVR) achieved due to IFN or PegIFN/R does not universally
prevent progression to HCC, which develops in up to 3.9% of these
individuals [12–17]. Contrary to prevailing opinion based on the
currently available clinical testing for HCV RNA, clinical diagnosis
of SVR does not reflect molecular eradication of HCV, as
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evidenced by assays of enhanced sensitivity supplemented with
examining of serial samples of plasma, peripheral blood mononu-
clear cells (PBMC) and, when available, liver biopsies, and by
procedures enriching HCV in test material by amplifying viral RNA
recovered from larger amounts of serum, liver biopsy material and/
or from mitogen-stimulated PBMC [6–9,18–20]. Further, the
detection of HCV RNA replicative (negative) strand is not
uncommon in OCI, particularly when ex vivo stimulated PBMC
and liver biopsy material are analysed [6,8,11,20]. Since discovery
of OCI in 2004, persistence of HCV after SVR was the subject of
studies by different groups which delineated virological and some
unique immunological properties of this infection [6–9,21–23].
Among others, OCI displays a distinct profile of antiviral cytokine
expression in PBMC when compared to either CHC or healthy
individuals, shows an antagonistic relation between HCV and IFN-
a expression in PBMC, and that HCV replication in this
compartment can be completely eliminated by activation of
endogenous IFN-a [22,23]. Nonetheless, OCI is rarely investigated
and knowledge on this subject remains incomplete. To broaden
characterization of this infection entity, in particular to learn about
the fate of HCV during and shortly after completion of otherwise
clinically successful treatment with PegIFN/R, we re-examined,
using highly sensitive HCV genome detection methods, serial
plasma and, in some cases, PBMC samples collected prior to, during
and after completion of PegIFN/R therapy from patients with CHC
who finally achieved clinical SVR.
Materials and Methods
Ethics Statement
The study was approved by the Weill Cornell Medical College
institutional review board and was performed in accordance with
the Declaration of Helsinki. The samples were collected after
signing written informed consent.
Patients and samples
Serial plasma samples (n = 56) from 9 patients (3 men and 6
women; ages 38 to 62), who clinically resolved CHC in response to
treatment with PegIFN/R, and sequential PBMC samples (n = 23)
from 3 of them were investigated (Table 1). The patients were
infected with HCV genotype 1 or 2 (Table 1). The origin and the
route of HCV infection were undetermined; however none of the
patients was an active drug user during treatment or follow-up.
None of them also was co-infected with hepatitis B virus (HBV) or
human immunodeficiency virus or was receiving immunosuppres-
sive or anti-cancerous therapy. All patients received PegIFN/R
treatment for 24 or 48 weeks (wks) with the exception of 6/F, 7/F
and 2/F who were treated for 25, 44 or 68 wks, respectively
(median treatment time for all 9 patients was 43.3 wks) (Table 1).
The therapy resulted in the decline of plasma HCV RNA to
undetectable levels, as measured by clinical laboratory tests (see
below), and in normalization of liver enzymes, i.e., alanine
aminotransferase (ALT) and aspartate aminotransferase (AST),
starting within 3 to 4 wks after initiation of PegIFN/R. In regard
to plasma samples, 11 samples from a total of 19 collected prior to
initiation of the therapy (pre-treatment samples) were available for
re-examination. These 11 samples were obtained between week 21
and one before the start of treatment (median time of collection
8.1 wks). Among 55 plasma samples collected during the
treatment period (on-treatment samples), 25 were available for
re-evaluation (Table 1). Also, from 34 plasma samples collected
during follow-up lasting for up to 88 wks after completion of
PegIFN/R therapy (post-treatment samples), 20 were available for
reanalysis. The time of the last sample collection from individual
patients ranged between 12 and 88 wks post-treatment (median
33.1 wks). Plasma was stored in 1-mL aliquots at 280uC until re-
tested. One 1-mL aliquot per sample was available for investiga-
tion.
Serial PBMC samples collected at the time of plasma acquisition
were available from 3 of the patients (Table 1). In total, 23 PBMC
samples were investigated of which 5 were obtained before, 10
during and 8 up to 88 wks after completion of PegIFN/R
treatment. PBMCs were stored in liquid nitrogen at 56106 to
16107 cells per vial. One vial per sample was available for this
study.
PBMC isolation and mitogen stimulation
PBMCs were isolated from whole blood by density gradient
centrifugation. After washing, cells were suspended in heat-
inactivated fetal calf serum (FCS) with 10% DMSO, progressively
cooled down to 280uC, and stored in liquid nitrogen. A two-step
approach was used to prepare PBMCs for evaluation of HCV
expression. In the first approach when approximately 16107 cells
were available for investigation, the cells were thawed, extensively
washed, and split to two equal portions. One of the portions was
spun down and the cell pellet was immediately subjected to RNA
extraction. These cells were designated as untreated. The
remaining portion of the cells, as well as PBMC samples that
contained approximately 56106 cells, were suspended in 5 ml of
RPMI 1640 medium with 10% FCS, 2 mM glutamine, 50 U of
penicillin/ml, 50 mg of streptomycin mL-1, 0.1 mM nonessential
amino acids (all from Invitrogen Life Technologies, Burlington,
Ontario, Canada), 5 mg/ml of phytohemagglutinin (PHA; Sigma-
Aldrich Mississauga, Ontario, Canada) and 20 U/ml human
recombinant interleukin-2 (IL-2; Roche Molecular Diagnostics,
Pleasanton, CA), and cultured for 72 hours as reported [5,6,11].
These ex vivo stimulated cells were designated as treated cells.
RNA extraction and cDNA transcription
Total RNA was extracted from 250 ml of plasma and, if the
sample was HCV RNA nonreactive, from the remaining 750 ml of
the same sample using Trizol LS reagent (Invitrogen) [6,11].
Untreated PBMC and those cultured in the presence of PHA and
IL-2 (treated cells) were extracted with Trizol (Invitrogen). With
each RNA extraction, a mock sample of sterile bi-distilled water
(contamination control), serum or PBMC from a healthy donor
(negative control) and serum or PBMC from a patient with serum
HCV RNA-reactive CHC (positive control) were included. RNA
from cells (2 to 4 mg) and all RNA extracted from 250 ml or 750 ml
of plasma were transcribed to cDNA with Moloney murine
leukemia virus reverse transcriptase (Invitrogen), as reported
[6,11].
Detection of HCV RNA positive and negative strands
For detection of HCV RNA positive (vegetative) strand, reverse
transcriptase-polymerase chain reaction (RT-PCR) was applied
using primers specific for the HCV 59-untranslated region (59-
UTR), cycling conditions and quantification standards reported
before [6,11]. In selected samples (depending upon availability of
test material), the presence of the HCV RNA positive strand was
also examined by amplification with the virus E2 region-specific
primers, as reported [6]. Detection of OCI normally requires two
rounds of cDNA amplification by PCR, direct and nested,
following stringent precautions typical when working with nested
PCR, and inclusion of appropriate contamination and negative
controls at each step of RNA and cDNA preparation, and PCR
amplification [6,7]. In all instances, signal specificity was
confirmed by nucleic acid hybridization (NAH) using 32P-labeled
HCV during and after Treatment of CHC
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recombinant HCV 59-UTR-E2 fragment as a probe [6].
Sensitivity of the RT-PCR/NAH assays with either 59-UTR or
E2 region-specific primers was ,10 vge/ml or ,2.5 vge/mg RNA.
Overall, the underlying methodology and the resulting sensitivity
of these assays employed in the current study were closely
comparable to those of the PCR/NAH assays previously
developed and applied for detection of occult HBV and
woodchuck hepatitis virus infections [24,25]. HCV RNA negative
(replicative) strand was detected by RT-PCR/NAH using rTth
DNA polymerase, as described in detail before [6,26]. This assay
detects ,102 copies of the correct (negative) strand, while
identifying $106 vge of the positive strand [6,26]. Specificity of
PCR amplicons and validity of the controls was routinely
confirmed by NAH. In every analysis, a number of negative and
contamination controls were included, as described before [6].
Cloning, sequencing and analysis of the HCV 59-UTR
To assess possible sequence variations and compartmentaliza-
tion of HCV, 59-UTR amplicons were cloned using the TOPO-
TA cloning kit (Invitrogen). The highly conserved 59-UTR was
chosen because it would allow for reliable identification of most
unwavering sequence variants. Ten or 20 randomly selected clones
were analyzed from each PCR product derived from 7 pairs of
plasma and PBMC samples collected at the same time points of
follow-up (with one exception) prior to, during or after completion
of PegIFN/R treatment from 2 patients (5/M and 8/F) from
whom sufficient amounts of sample material were available. The
sequence was determined in both directions using universal
forward and reverse M13 primers, and the ABI-Prism 7000
Sequence Detection System (Applied Biosystems, Streetsville,
Canada). The resulting sequences were aligned using Sequencher
software version 4.7 (Gene Codes Corp., Ann Arbor, MI). The
HCV subgenotype-specific sequences D00944 and AF169005 for
2a genotype, and D10988 and AF238486 for 2b genotype from
GenBank were used as the references. The phylogenetic relation-
ships of the variant 59-UTR sequences identified in plasma and
PBMC of 5/M and 8/F patients were examined by the maximum-
likelihood method [27].
Statistical analysis
Results were analyzed by Chi-Square test using SPSS Statistics
software version 19.0 (IBM, Armonk, New York State, USA).
Differences between sample groups were considered to be
significant when P values were below or equal to 0.05.
Results
HCV RNA detection in clinical assay virus-negative
plasma samples collected during or after antiviral
treatment
Using the standard clinical assays, plasma HCV loads in
samples collected prior to initiation of PegIFN/R therapy ranged
between 1.56104 and 2.46106 IU/ml (mean 4.56105 IU/ml). All
11 samples available for re-examination were, as expected, HCV
RNA reactive when RNA extracted from 250-ml plasma was
assayed by RT-PCR/NAH (Table 2). However, among 55
samples collected in total during the treatment period only 3
(5.4%) obtained from 3 different patients were reactive for HCV
RNA by the clinical assays at levels not exceeding 1.16103 IU/ml.
When 25 of the 55 samples were re-tested by RT-PCR/NAH
using RNA from either 250 ml or 750 ml of plasma, 17 (68%) were
identified to be HCV RNA positive (Table 2). These positive
samples were obtained at different time points of PegIFN/R
treatment from 8 of 9 patients examined, including samples
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collected at the end or within one month prior to completion of
the therapy from 4 of the patients. It should be noted that from 2/
F patient who was found HCV RNA nonreactive during therapy
only a single plasma sample collected through that period was
available for re-examination; however, subsequent plasma samples
from the same individual were virus reactive for up to 59 wks post-
treatment. Further, amongst 34 post-treatment samples none was
HCV RNA reactive by the standard clinical assays. Nonetheless,
among 20 of these 34 samples re-examined, which were collected
between 18 and 88 wks after treatment, 9 (45%) were HCV RNA
positive by RT-PCR/NAH. Thus, virus was detected in 8 of the 9
samples when RNA extracted from 750 ml of plasma was tested
(Table 2). These 9 reactive samples originated from 4 of the 9
individuals studied. In these 4 patients, virus reactive samples were
collected at 23–24 or 59 wks post-treatment. Overall, using as
template RNA extracted from 750 ml of plasma acquired either
during or after completion of PegIFN/R therapy gave more than a
3-fold greater rate of HCV RNA detection than in RNA isolated
from 250-ml samples when tested by RT-PCR/NAH, i.e., 19/38
(50%) vs. 7/45 (15.5%), respectively (P = 0.001) (Table 2). Overall,
among 45 on- or post-treatment samples re-examined, of which
only 3 (6.6%) were HCV RNA reactive by clinical assays, 26
(57.7%) were positive for virus by more sensitive RT-PCR/NAH,
giving in total an 8.7-fold increase in detection of plasma HCV
RNA (P,0.0001).
Expression of HCV RNA in PBMC of CHC patients prior to,
during and after antiviral treatment
In the first instance, when a cell number of about 16107 was
available for investigation, PBMC (i.e., untreated cells) were
directly subjected to RNA extraction and HCV RNA expression
was examined. As showed in Table 2, 6 of 23 (26.4%) samples
tested under such conditions were HCV RNA positive strand
reactive. Taking advantage of the previous finding that mitogen
stimulation of lymphoid cells from HCV-infected patients
enhanced virus replication and, in consequence, virus detection
[6,11,18,20], the initially HCV RNA-negative PBMC samples or
those in which the cell number was close to 56106 were cultured
in the presence of PHA and IL-2 and then HCV RNA expression
assessed. This ex vivo stimulation allowed detection of HCV in an
additional 11 (i.e., 11/17; 54.7%) samples. Overall, virus was
identified in 17 of 23 (73.9%) PBMC samples tested (Table 2).
Among them, 8 of 10 (80%) obtained during PegIFN/R treatment
and 4 of 8 (50%) acquired after completion of therapy were HCV
RNA positive.
Evidence of HCV replication in PBMC of patients on and
after anti-HCV therapy
All PBMC identified to be HCV RNA positive strand reactive
were evaluated for HCV RNA negative (replicative) strand using
the highly sensitive RT-PCR/NAH assay [6,11,26]. Since this
replication intermediate normally occurs at a much lower copy
number than the positive strand and the assay detecting the
negative strand is approximately 10 to 100-fold less sensitive than
that used for the positive strand identification [6,26], HCV RNA
negative strand expression was examined only in PBMC found
reactive for the positive strand. Overall, this form of HCV RNA
was detected in 10 out of 16 (62.5%) PBMC samples investigated
(Table 3 and Fig. 1C). Among the negative strand reactive
PBMCs, 4 out of 4 samples were collected prior to treatment, 4 of
8 during ongoing therapy, and 2 of 4 post-treatment (Table 3).
The reactive post-treatment samples were obtained at 12 wks after
cessation of PegIFN/R therapy.
Detection of HCV in paired plasma and PBMC samples
during and after antiviral treatment
Examination of HCV expression in serial plasma and PBMC
samples collected at the same time points of follow-up was possible
in 3 of the patients investigated. Considering HCV RNA detection
in either 250-ml or 750-ml plasma samples and in either untreated
or ex vivo stimulated lymphoid cells (Table 3), among 22 plasma-
PBMC pairs examined, 13 (59.1%) were HCV positive in both
plasma and PBMC, while virus was detected in 5 (22.7%) of the
pairs in plasma only and in 4 (18.2%) other pairs in PBMC alone.
Further, among 18 plasma-PBMC pairs collected during the
treatment or post-treatment periods, 9 (50%) plasma-PBMC pairs
were HCV positive in both compartments, while 5 (27.8%) and 2
(22.2%) were HCV reactive in plasma and PBMC, respectively.
Identification of HCV RNA in serial plasma and PBMC
samples collected at the same time points of follow-up from 8/F
patient infected with HCV genotype 2a and treated for 48 wks
with PegIFN/R was shown in Figures 1A and 1B, respectively.
Figure 1C illustrates detection of HCV RNA replicative strand in
PBMC samples identified to be virus RNA positive strand reactive.
Persistence of HCV variants in plasma and PBMC during
and after antiviral therapy
To assess whether otherwise successful treatment of CHC had
an effect on the diversity of HCV variants, clones of 59-UTR
amplicons derived from 5/M and 8/F plasma and PBMC
collected before, during and after completion of PegIFN/R
administration were sequenced in both directions. Two types of
comparisons were performed; one using as the baseline the HCV
sequence identified in plasma of a given individual prior to
initiation of therapy and second using as references two relevant
sequences from GenBank for each of the HCV subgenotype of
interest. The analyses showed that the point mutations unique to a
given individual already existed in the pre-treatment plasma and/
or PBMC, that the majority of these mutations persisted through
therapy and follow-up, and that some variants tended to spread
with time from one compartment to another, i.e., from plasma to
PBMC (e.g.,126insC, G151A, A256G and C271T in 58/F) or vice
versa (e.g., G97A and A115G in 58/F) (Table 4). Considering the
HCV sequence identified in the pre-treatment plasma, the results
indicated that HCV variants unique to PBMC appeared prior to
as well as during treatment and some of them persisted through
the whole observation period. It is of note that two point
mutations, G255T and A275C, which were consistently detected
in all clones tested (n = 100) from plasma or PBMC of 8/F, were
distinct from the 2b genotype sequences reported in GenBank
used for comparison (data not shown). Overall, the analysis
confirmed that HCV not only persisted but also suggested that its
replication progressed during the period of administration of
PegIFN/R since new variants appeared and spread from one
compartment to another. The 59-UTR variants and wild-type 59-
UTR sequences found in 5/M and 8/F patients have been
deposited in GenBank under accession numbers KF548005-
KF548035.
The phylogenetic tree analysis of the variant 59-UTR sequences
identified in 5/M and 8/F showed the lack of separate clustering
of plasma and PBMC derived variants (Fig. 2). This was consistent
with the finding that the same variants occurred both in plasma
and PBMC, and that they tended to spread from one compart-
ment to another during follow-up (Table 4).
HCV during and after Treatment of CHC
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Discussion
This study demonstrated that HCV is not cleared during
ongoing administration of standard PegIFN/R therapy or after its
completion even when the treatment lowers circulating HCV to
the levels undetectable by clinical testing and was finally capable of
inhibiting progression of CHC. While persistence at low levels of
HCV in plasma or sera in the context of detectable antibodies to
HCV (anti-HCV), undetectable serum HCV RNA by clinical
testing, and essentially normal levels of liver enzymes has been
reported in individuals long after clinical resolution of CHC
following treatment with IFN or PegIFN/R [5,6,8,9,11,20], the
detection of HCV and its replication during ongoing treatment
with PegIFN/R when the virus genome became undetectable by
clinical assays has not yet been examined and our study is the first
in this regard. Although this finding per se was expected,
considering frequent detection of OCI after clinically apparent
SVR when methods enhancing virus identification were used
[6,11,18,19,20], it adds a new dimension to the robustness of HCV
infection in the face of antiviral treatment even if such treatment is
ultimately capable of inhibiting progression of the disease. It also
confirms inability of the standard PegIFN/R therapy to
completely eradicate HCV from an infected host.
In addition to persistence of HCV in plasma during OCI, virus
and its replicating genomes were uncovered in PBMC and liver
biopsies in individuals for many years after having been considered
to be clinically cured of hepatitis C [5–9,11,20,22]. In regard to
infection of PBMC, different subsets of circulating immune cells
were found to carry HCV, its RNA replication strand, displayed
intracellularly virus protein (i.e., nonstructural protein 5a; NS5a),
and virus sequence variants not encountered in the patients’
plasma or liver [8,20,28–30]. Also, cultured PBMC from
individuals with OCI continuing after SVR due to PegIFN/R
therapy released HCV virion-like particles identifiable by im-
munoelectron microscopy with anti-HCV E2 antibodies and
transmitted infection to virus-naı¨ve human T lymphocytes in
culture [5]. Taken together, the accumulated data showed that
HCV residing in immune cells fully retains biological competence,
including infectivity [5,31]. These and other findings prove that
immune cells, including T lymphocytes, are targets of naturally
occurring virus, they are reservoirs of replicating HCV regardless
of symptomatic or occult appearance of infection and, since these
cells are readily accessible, they can be utilized for evaluation of
the status of HCV replication during infection and progression of
antiviral treatment [32]. In this context, the detection of HCV
positive and, in some cases, virus negative (replicative) strands in
PBMCs in the current study is indicative that these cells
Table 3. Detection of HCV RNA positive strand in plasma and HCV RNA positive and negative (replicative) strands in parallel PBMC
samples from patients who clinically resolved CHC due to PegIFN/R treatment.
HCV RNA positive strand
HCV RNA negative
strand
Plasma PBMC
Patient Week of treatment Phase of treatment 250 ml or 750 ml Untreated (naive) Treated (stimulated) PBMC
5/M 25 Before POS NT POS POS
4 During POS POS NT POS
24 During NEG POS NT NEG
+4 After POS NT POS NEG
+12 After POS NT POS POS
+24 After POS NEG NEG NA
7/F 214 Before POS NT POS POS
4 During POS NEG POS NEG
25 During NEG NEG POS POS
29 During NEG NEG POS NEG
44 During POS NT NEG NA
+6 After NEG NEG NEG NA
+88 After NEG NEG NEG NA
8/F 214 Before POS NEG POS POS
24 Before POS NT POS POS
4 During POS POS NT NEG
12 During POS POS NT POS
18 During No sample POS NT POS
24 During POS NEG NEG NA
48 During POS NT NEG NA
+4 After POS POS NT NEG
+12 After NEG NT POS POS
+24 After POS NT NEG NA
M, male; F, female; 2, prior to initiation therapy; +, after completion of therapy; POS, positive; NEG, negative; NT, not tested; NA, not available.
doi:10.1371/journal.pone.0080078.t003
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constituted a virus reservoir during both ongoing PegIFN/R
treatment and after its completion.
In regard to the above, it is of interest to note that human
recombinant IFN-a 2b is capable of total elimination of HCV
replication in cultured normal human T lymphocytes infected de
novo with different HCV genotypes at concentration of
1000 U mL-1 [5,31; MacParland and Michalak, unpublished
data]. Also, replication of HCV in T cells of patients with CHC or
OCI persisting after SVR can be completely abrogated by
activation of endogenous IFN-c in CHC but of IFN-a in OCI
after ex vivo stimulation of the cells with a mitogen prompting
proliferation of T cells [23]. These data suggest that IFN-a has in
fact ability to totally purge HCV from infected cells, at least in the
immune cell compartment.
The bidirectional sequencing analysis of the 59-UTR encom-
passing the virus internal ribosomal entry site (IRES) suggested
nucleotide polymorphisms between plasma and PBMC obtained
at the given time points of follow-up, either before, during or
following PegIFN/R treatment, which were particularly apparent
in samples from 8/F patient (Table 4). The existence of HCV
polymorphisms in PBMC comparing with plasma and liver has
been previously reported in patients with CHC or OCI and in
individuals after SVR with a past exposure to HBV [11,20,28,29].
In this study, a minority of variants identified before or during
therapy were not detectable thereafter, suggesting that the breadth
of HCV polymorphism tended to decline after cessation of the
therapy. However, as already noted, the majority of the point
mutations detected prior to the initiation of PegIFN/R therapy
persisted throughout the treatment and the post-treatment periods.
Moreover, they showed an inclination to spread from one
compartment of virus occurrence to another, implying that the
antiviral treatment was without meaningful effect on their fate.
This trend to spread from PBMC to plasma or vice versa was
confirmed by the phylogenetic tree analysis of the 59-UTR
sequences identified during the observation period of 5/M and 8/
F patients, which showed the lack of segregation to separate
clusters of the variants detected in plasma and PBMC (see Fig. 2).
Some of the variants detected were reported before. Thus,
126insC mutation found in plasma of 8/F prior to treatment
and then in PBMC and plasma during and after PegIFN/R
therapy has been reported for HCV derived from brain [33], while
125delC detected in PBMC during treatment of 8/F patient was
previously found in PBMC of a patient with occult HCV infection
[11].
Figure 1. Expression of HCV RNA positive strand in serial plasma and PBMC samples and HCV RNA negative (replicative) strand in
PBMC prior to, during and after completion of PegIFN/R treatment of 8/F patient with the initial diagnosis of CHC. (A) HCV RNA
positive strand detection using total RNA extracted from 250 ml or 750 ml of plasma. (B) HCV RNA positive strand identification using 2 mg of total
RNA extracted from either mitogen-treated (*) or native (untreated) PBMC. (C) Detection of HCV RNA negative strand in HCV RNA positive strand
reactive PBMC samples shown in B. Plasma and PBMC were collected in parallel (except 4A PBMC sample) at the time points (weeks) indicated under
panels A and B. Minuses before week numbers indicate sample collections prior to initiation of PegIFN/R therapy, while pluses indicate collections
after completion of the treatment. As positive controls for HCV RNA positive strand detection, RNA extracted from equivalent of 10 ml of HCV RNA-
positive plasma (panel A) or 1 mg RNA from PBMC (panel B) of a patient with active CHC, and serial 10-fold dilutions of recombinant HCV 59-UTR-E2
(rHCV UTR-E2) fragment carrying indicated copy numbers/reaction were used. For HCV RNA negative strand detection, 2 mg of total RNA from PBMC
of the same control CHC patient as in panels A and B, and synthetic HCV RNA positive strand (sHCV RNA pos) and HCV synthetic RNA negative strand
(sHCV RNA neg) at 104 copies/reaction were used as positive and specificity controls. Water amplified in direct (DW) and nested (NW) reactions and a
mock (M) extraction served as contamination controls. Positive signals showed the expected 244-bp oligonucleotide fragments. Numbers under the
panels represent relative densitometric units (DU) given by hybridization signals.
doi:10.1371/journal.pone.0080078.g001
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Figure 2. Phylogenetic analysis of the HCV 59-UTR variants found in plasma and PBMC from patients 5/M and 8/F obtained prior to,
during and after PegINF/R therapy. The numbers 5 and 8 identify patient 5/M and 8/F, respectively. M indicates the variant and wild wild-type
sequence found in the majority of the clones derived from a given patient prior to, during and after therapy. B stands for before treatment, D during
treatment, and A after treatment with PegIFN/R. The variants from plasma are marked with S, while those from PBMC with C. The numbers 1–20
indicate individual clones. The genotype 2a and 2b nucleotide sequences serving as references are marked as Ref.
doi:10.1371/journal.pone.0080078.g002
Table 4. Single-nucleotide polymorphisms in the HCV 59-UTR sequence in sequential plasma and PBMC samples obtained from
patients with CHC prior to, during and after treatment with PegIFN/R.
Phase of treatment
Age/sex Genotype Sample Before During After
Time of collection (week): 25{ 4{ +12{
5/M 2b plasma A177G (1) A177G (1) A177G (2)
PBMC A177G (1) A177G (1)
Time of collection (week): 24` 12{ +4{ +12{ +24{
8/F 2a plasma 126insC (1) A115G (1) A115G (1) NA A115G (1)
G151A (2) 126insC (1) 126ins (2) 126insC (1)
A256G (1) C236T (1) C271T (2) C271T (1)
C271T (1) C271T (1)
PBMC G97A (1) 126insC (1) 126insC (2) 126insC (2) NA
A115G (3) 125delC (1) C271T (2) C271T (2)
A256G (1)
C271T (1)
M, male; F, female; PBMC, peripheral blood mononuclear cells; 2, prior to initiation of therapy; +, after completion of therapy; NA, not available;
{, 10 clones per sample sequenced;
`, 20 clones per sample sequenced.
doi:10.1371/journal.pone.0080078.t004
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Treatment with PegIFN/R inhibits progression of CHC in 40%
to 50% of those chronically infected with HCV genotype 1
without benefiting the remaining infected with this genotype [34].
Nonetheless, HCV persists for years, if not decades, even in those
who achieved clinical SVR at levels which are only occasionally
detectable by clinical molecular tests of improved sensitivities
[5,6,8,9,35]. The relevance of this low level HCV persistence to
virological relapse after SVR, as defined by detection of HCV
RNA by clinical assays, appears to be low or very low based on the
data from pertinent clinical trials and related prospective studies.
These data indicate that the late reappearance of HCV detectable
by clinical tests among responders to IFN or PegIFN/R is ranging
from that close to none to 11.6% [36–38]. However, the results
outside clinical trials show that virological and clinically evident
relapse after IFN-induced SVR happens and is usually linked to
situations where the host’s immune system is compromised due to
either immunosuppressive treatment or comorbid disease [39–41].
The accumulated data imply that it will be prudent to monitor the
molecular markers of HCV infection and liver function enzymes in
patients with a history of HCV infection and SVR who are
subjected to temporal or prolonged immunosuppressive therapies
and/or suffer from diseases diminishing the host’s immune
surveillance, as it has become common in recent years for
individuals with a past exposure to HBV and persistent occult
HBV infection [42,43].
Currently PegIFN/R treatment remains the most commonly
utilized approach against CHC, although patients infected with
HCV genotype 1 benefit from supplementing this therapy with
direct acting antivirals (DAAs) targeting virus proteases or
polymerase. While it is expected that new generations of DAAs
will replace the need for IFN-a use in the majority of patients
infected with different HCV genotypes, although IFN-a may
remain as part of the treatment scheme for patients who relapse
after DAA therapy. Nonetheless, to fully recognize the sterilizing
potency of new DAAs in the context of the extremely high
mutagenic capacity of HCV and the virus’ resulting ability to
generate drug resistant mutants, the DAA effects on virus
replication at extrahepatic sites, particularly in immune cells,
should be routinely assessed since these cells also are the site of
virus active propagation. There are very limited data in this
regard. However, telaprevir, an HCV-specific protease inhibitor
recently approved for clinical use (VX-950; Vertex Pharmaceu-
ticals, Cambridge, MA) [44], has been shown to totally inhibit
replication of native, patient-derived HCV infecting Molt4 T cells
at the cell nontoxic concentration of 4 mM, as our recent study
demonstrated [26]. This indicates that this DAA has the ability to
enter and inhibit propagation of HCV in cells other than
hepatocytes.
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